[1] Bellone M, et, al. Expression of αV-integrins in uterine serous papillary carcinomas; implications for targeted therapy with intetumumab (CNTO 95), a fully human antagonist anti-αV-integrin antibody. Int J Gynecol Cancer. 2011 Aug;21(6):1084-90. DOI:
10.1097/IGC.0b013e3182187324[2] Gonzalez-Nicolini V, et, al. Premedication and Chemotherapy Agents do not Impair Imgatuzumab (GA201)-Mediated Antibody-Dependent Cellular Cytotoxicity and Combination Therapies Enhance Efficacy. Clin Cancer Res. 2016 May 15;22(10):2453-61. DOI:
10.1158/1078-0432.CCR-14-2579